Olezarsen Sodium is an antisense oligonucleotide commercialized by Ionis Pharmaceuticals, with a leading Pre-Registration program in Familial Chylomicronemia (Type I Hyperlipoproteinemia). According to Globaldata, it is involved in 12 clinical trials, of which 5 were completed, and 7 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Olezarsen Sodiums valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Olezarsen Sodium is expected to reach an annual total of $256 mn by 2034 in the US based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Olezarsen Sodium Overview
AKCEA-APOCIIILRx is under development for the treatment of severe high triglycerides (SHTG) and high triglycerides with type 2 diabetes, familial chylomicronemia syndrome and atherosclerotic cardiovascular disease. It is administered subcutaneously. The drug candidate is an GalNAc3 conjugated antisense oligonucleotide which acts by targeting the apolipoprotein C-III protein (ApoC-III). The development of drug candidate is based on ligand-conjugated antisense (LICA) technology.
Ionis Pharmaceuticals Overview
Ionis Pharmaceuticals (Ionis), formerly Isis Pharmaceuticals, focuses on the discovery and development of RNA-targeted drugs. The company develops medicines to treat various diseases including cancer, pulmonary, cardiovascular diseases, neurological and infectious diseases. Its major products include Spinraza for spinal muscular atrophy, Tegsedi for neuropathy, Waylivra for familial chylomicronemia syndrome, Qalsody for superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), and Wainua for polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN). Ionis also has a pipeline of products in different phases of clinical trials. It develops products based on its proprietary antisense technology. The company partnered with other pharmaceutical companies to develop a range of products in different therapeutic areas. The company sells its products in North America and Europe. Ionis is headquartered in Carlsbad, California, the US.
The company reported revenues of (US Dollars) US$787.7 million for the fiscal year ended December 2023 (FY2023), an increase of 34.1% over FY2022. The operating loss of the company was US$340.3 million in FY2023, compared to an operating loss of US$417.9 million in FY2022. The net loss of the company was US$366.3 million in FY2023, compared to a net loss of US$269.7 million in FY2022.
The company reported revenues of US$119.5 million for the first quarter ended March 2024, a decrease of 63.2% over the previous quarter.
For a complete picture of Olezarsen Sodiums valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
